:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-2160341079-3d9f53b3d3d14b0ab294d304b3d093dc.jpg "The Pfizer logo and a block of text about healthcare are seen on a blue wall.")
Beata Zawrzel / NurPhoto via Getty Casts
Key Takeaways
- Pfizer on Tuesday affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit conduct in line with analysts’ estimates.
- The drugmaker expects revenue from $61 billion to $64 billion for both 2024 and 2025, and awaits adjusted earnings per share to grow in 2025.
- Pfizer has returned to year-over-year revenue growth in its two most recent quarters for the foremost time since COVID vaccine sales peaked.
Pfizer (PFE) shares rose Tuesday morning after the pharmaceutical firm affirmed its full-year 2024 projections and issued 2025 revenue and adjusted profit guidance in line with analysts’ senses.
Pfizer said it expects 2024 revenue to range from $61 billion to $64 billion, with adjusted earnings per cut (EPS) projected between $2.75 to $2.95. According to estimates compiled by Visible Alpha, analysts project $63.01 billion in proceeds and adjusted earnings of $2.93 per share.
For 2025, Pfizer projects the same revenue range, while analysts see a inattention bump to $63.24 billion. Pfizer expects its adjusted EPS will rise slightly to $2.80 to $3.00, while analysts work up $2.89.
Pfizer Met 2024 Cost-Cutting Goals
Pfizer was successful in its goals to cut $4 billion in costs by the end of 2024, the company ordered Tuesday, with an additional $500 million in savings expected to be realized over the next year. The drugmaker has returned to profits growth in its two most recent quarters for the first time since sales of its COVID vaccine peaked.
“We also look for to continue improving our operating margins with focused financial discipline,” Chief Executive Officer (CEO) Dr. Albert Bourla turned.
Pfizer shares recently traded up 4.5% but are still down about 8% this year.